Glucose, 5% 250 ml 10 pcs
€1.00
Out of stock
(E-mail when Stock is available)
Glucose enhances redox processes in the body, improves the antitoxic function of the liver, increases the contractile activity of the myocardium, and is a source of easily digestible carbohydrates.
Active ingredient
Dextrose
How to take, the dosage
Intravenous (drip). The drug is usually injected into a peripheral or central vein.
Interaction
Concomitant use of catecholamines and steroids reduces dextrose (glucose) absorption.
Special Instructions
Since patients with diabetes mellitus, renal insufficiency or those in acute critical condition may have impaired glucose (dextrose) tolerance, their clinical and biological parameters, in particular plasma electrolyte concentration, including magnesium or phosphorus, blood glucose concentration should be monitored particularly carefully. If hyperglycemia is present, the rate of drug administration should be adjusted or short-acting insulin should be prescribed. Usually glucose is fully absorbed by the body (normally not excreted by kidneys), so the appearance of glucose in the urine may be a pathological sign.
In case of prolonged administration or administration of dextrose in high doses it is necessary to monitor the concentration of potassium in plasma and if necessary to administer additional potassium to avoid hypokalemia.
In episodes of intracranial hypertension, careful monitoring of blood glucose concentration is necessary.
The use of dextrose solutions may lead to hyperglycemia. Therefore, they are not recommended after acute ischemic stroke, as hyperglycemia is associated with increased ischemic brain damage and prevents recovery.
Particularly careful clinical monitoring is required at the beginning of intravenous administration of the drug.
For rehydration therapy carbohydrate solutions should be used in combination with electrolyte solutions to avoid electrolyte imbalance (hyponatremia, hypokalemia).
The glucose concentration and electrolyte content in the blood, the water balance as well as the acid-base state should be monitored. Use only clear solution without visible inclusions and with no damage to the package. The solution should be administered immediately after connection to the infusion system.
The solution should be administered using sterile equipment in compliance with aseptic and antiseptic rules.
To avoid air embolism air should be removed from the infusion system with the solution.
Do not connect the containers in series to avoid air embolism, which may occur due to sucking in air from the first container before the injection of the solution from the second container is completed.
Infusing intravenous solutions contained in soft plastic containers at increased pressure to increase flow rates may result in an air embolism if the residual air in the container is not completely removed prior to injection.
Using an IV system with a vapor outlet may result in an air embolism if the vapor outlet is open. Soft plastic containers with these systems should not be used.
Additives may be administered before infusion or during infusion through the infusion site (if there is a special port for drug administration).
Adding other drugs to the solution or violation of the injection technique may cause fever due to possible ingestion of pyrogens.
In case of adverse reactions the infusion should be immediately stopped.
When adding other drugs before parenteral administration it is necessary to check the isotonicity of the resulting solution.
Complete and thorough mixing under aseptic conditions is mandatory.
Solutions containing additional substances should be used immediately, their storage is prohibited.
When introducing additional nutrients the osmolarity of the resulting mixture should be determined before starting the infusion.
The resulting mixture should be administered through a central or peripheral venous catheter depending on the final osmolarity.
Compatibility of additionally administered drugs should be evaluated before adding them to the solution (similar to the use of other parenteral solutions). Assessment of compatibility of additionally administered drugs with the drug is the responsibility of the doctor. The resulting solution should be checked for discoloration and/or the appearance of precipitate, insoluble complexes or crystals. The instructions for use of the added drugs should be studied.
From the microbiological point of view, the diluted drug should be used immediately. Exceptions are dilutions prepared under controlled and aseptic conditions. Otherwise, once the solution has been prepared, the terms and conditions of storage prior to administration are the responsibility of the user.
Children
Neonates, especially those born prematurely or with low body weight, have an increased risk of hypo- or hyperglycemia, so careful monitoring of blood glucose concentration is necessary during intravenous administration of dextrose solutions to avoid distant undesirable effects. Hypoglycemia in newborns may lead to prolonged seizures, coma and brain damage. Hyperglycemia is associated with intraventricular hemorrhage, delayed bacterial and fungal infections, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged hospitalization and mortality.
To avoid potentially fatal overdose of intravenous drugs in neonates special attention must be paid to route of administration. For the treatment of “symptomatic” hypoglycemia, a 10% glucose solution is preferred. At the same time it is necessary to constantly monitor the blood glucose level and adjust it if necessary. It should be taken into account that newborns with different pathologies have different requirements for exogenous glucose. Abrupt termination of the infusion may cause hypoglycemia, therefore the glucose dose is gradually reduced and the glucose solution titration is stopped when the child maintains normoglycemia during glucose infusion at the rate of 4 mg/kg/min.
When a syringe pump is used for intravenous drug administration to newborns the container with the solution must not be left attached to the syringe.
When using an infusion pump, all system clamps must be closed before removing the system from the pump or disconnecting it, regardless of any device in the system that prevents free fluid flow.
Intravenous infusion devices and other drug administration equipment should be inspected regularly.
If the drug contains dextrose derived from corn, the use of the drug is contraindicated in patients with known intolerance to corn or corn products, since the following manifestations of hypersensitivity are possible: anaphylactic reactions, chills and fever.
For preparations in containers:
Containers should be disposed of after a single use.
Each unused dose should be disposed of.
Do not reassemble partially used containers.
Effect on ability to drive vehicles and vehicles:
Not applicable (due to inpatient use only).
Contraindications
Decompensated diabetes mellitus and non-sugar diabetes; hyperosmolar coma; hemodilution and extracellular hyperhydration or hypervolemia; hyperglycemia and hyperlactatemia: Severe renal failure (with oliguria or anuria); uncompensated heart failure; generalized edema (including pulmonary and cerebral edema) and cirrhosis of the liver with ascites; other known forms of glucose intolerance (such as metabolic stress); hypersensitivity to the drug components; administration of the solution within the first 24 h after head injury; use of the same infusion system as for hemotransfusion because of risk of hemolysis and thrombosis; patients with known intolerance to corn or corn products (when receiving dextrose from corn); contraindications to any drugs added to the glucose solution.
With caution:
Diabetes mellitus, intracranial hypertension, hyponatremia, pediatric age.
Side effects
Adverse reactions (ARs) are grouped by system and organ according to the MedDRA Dictionary and the WHO HP frequency classification:
Overdose
Symptoms: Prolonged infusion of the drug may result in hyperglycemia, glucosuria, hyperosmolarity, osmotic diuresis, and dehydration. Rapid infusion may create fluid accumulation in the body with hemodilution and hypervolemia, and if the body’s ability to oxidize glucose is increased, rapid administration may cause hyperglycemia. There may also be a decrease in plasma potassium and inorganic phosphate.
Similarities
Dextrose, Glucose Solution, Glucose
Weight | 0.287 kg |
---|---|
Shelf life | 2 years. |
Conditions of storage | In a dry place at a temperature of 5 to 30 ° C. |
Manufacturer | Hematec, Russia |
Medication form | solution for infusion |
Brand | Hematec |
Other forms…
Related products
Buy Glucose, 5% 250 ml 10 pcs with delivery to USA, UK, Europe and over 120 other countries.